Key clinical point: Oral selinexor induced durable responses with manageable adverse events in
patients with relapsed or refractory DLBCL.
Major finding: The overall response rate was 28%; 12% achieved a complete response and 17% a partial response.
Study details: A total of 267 DLBCL patients were enrolled in the single-arm, multinational, multicenter, open-label, phase 2 SADAL trial.
Disclosures: The study was sponsored by Karyopharm Therapeutics Inc., author funding. In sentence form. The authors reported various relationships with multiple pharmaceutical and biotechnology companies.
Kalakonda N et al. The Lancet: Haematology. 2020; 7:e511-22.